Determination of peripheral immune cell activity during treatment with either surgery or radiotherapy in patients with early stage non-small cell lung cancer.

Recruiting

• Conditions: lung cancer; lung carcinoma; 10038666; 10029107; 10038737

• Registration Number: NL-OMON39912
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

- Cytologically or histologically proven cT1-2aN0M0 NSCLC
- Patients >= 18 years old
- Patients should be fit to undergo both treatments in accordance with institutional protocols

Exclusion Criteria

- Patients with any sign of any co-existing infectious disease or immunosuppressive treatment (inhalation steroids are permitted)
- Mentally incapacitated subjects

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To determine whether an increase in CD8 activity can be observed in patients<br /><br>with early stage lung cancer who undergo surgical intervention or SABR.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The number and activation status of CD4 positive cells, monocytes, Tregs and<br /><br>MDSC in patients with early stage lung cancer undergoing curative intervention<br /><br>(surgery or SABR).</p><br>